Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase I study of hycanthone.

S S Legha, W E Grose, G P Bodey

    Cancer Treatment Reports
    |August 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Hycanthone treatment for metastatic cancer showed dose-related hepatotoxicity. A safe dose of 70 mg/m2/day for 5 days was identified for further clinical trials.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Serious complications of vascular catheter-related Staphylococcus aureus bacteremia in cancer patients.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·1992
    Same author

    Infectious complications of indwelling vascular catheters.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1992
    Same author

    Viral pneumonia in the immunocompromised adult with neoplastic disease: the role of common community respiratory viruses.

    Seminars in respiratory infections·1992
    Same author

    Lack of activity of amphotericin B in systemic murine fusarial infection.

    The Journal of infectious diseases·1992
    Same author

    Evaluation of strategies for central venous catheter replacement.

    Critical care medicine·1992
    Same author

    Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1992

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Metastatic cancer presents significant treatment challenges.
    • Identifying safe and effective drug dosages is crucial for clinical progression.

    Purpose of the Study:

    • To determine the maximum tolerable dose (MTD) of hycanthone in patients with metastatic cancer.
    • To evaluate the safety and dose-limiting toxicities of hycanthone administration.

    Main Methods:

    • Hycanthone was administered to 15 patients with metastatic cancer in 5-day courses every 3 weeks.
    • Dose escalation from 30 mg/m2/day up to 90 mg/m2/day was performed.
    • Adverse events, particularly hepatotoxicity, were closely monitored.

    Main Results:

    • Nausea and/or vomiting were the most frequent side effects, affecting 13 patients.

    Related Experiment Videos

  • Dose-limiting toxicity was toxic hepatitis, characterized by elevated serum transaminases and bilirubin.
  • Hepatotoxicity incidence was significantly higher at doses >= 80 mg/m2/day compared to <= 70 mg/m2/day.

    • Conclusions:

    • Hycanthone exhibits dose-related hepatotoxicity in patients with metastatic cancer.
    • A dose of 70 mg/m2/day for 5 days was determined to be a safe dose for Phase II studies.
    • Further investigation is warranted to balance efficacy and toxicity for hycanthone therapy.